Crescent Biopharma, Inc. (CBIO)
Market Closed
12 Dec, 20:00
NASDAQ (CM) NASDAQ (CM) Primary 
LSE $
14. 10
-1.21
-7.94%
$
198.25M Market Cap
- P/E Ratio
- Div Yield
101,112 Volume
- Eps
$ 15.31
Previous Close Day Range
14 15.57
Year Range
9.81 37
Want to track CBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Crescent Biopharma: Chasing The Summit Hype
Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody, aiming for first-in-human trials in late 2025. The company is well-funded, with over $150 million in cash and a manageable burn rate, supporting operations for 2–3 years. Risks include being behind competitors and the unproven clinical potential of their lead candidate, but sector hype remains strong.
Seekingalpha | 3 months ago
2025 © Marketlog. All Rights Reserved.
